文献速递脑血管病头痛与眩晕

CGRP靶向偏头痛治疗在有血管风险或卒中患者中的应用综述

CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review.
PubMed 文献 · Neurology · 2025-06-19

本文为叙述性综述,聚焦CGRP靶向治疗(单克隆抗体与gepants)在具有血管风险因素或脑血管病人群中的心血管与脑血管安全性。文章比较了新型药物与传统预防药物,指出既往卒中、蛛网膜下腔出血、心肌梗死或显著心血管共病患者的数据匮乏,并讨论了双重CGRP通路阻断这一新兴话题,基于现有证据提出结构化临床考虑以指导决策。

要点

  • CGRP靶向治疗在无主要风险因素者中心血管安全性较好,但高危人群证据有限。
  • 既往卒中、蛛网膜下腔出血、心肌梗死或显著心血管共病患者的数据明显不足。
  • 双重CGRP通路阻断(单抗联合gepants)的血管风险尚未被系统综述。

核心结论

  • CGRP靶向治疗在无主要心血管风险因素者中显示有利的心血管安全性,但在已确诊血管病或近期血管事件患者中证据有限。
  • 对既往卒中、蛛网膜下腔出血、心肌梗死或显著心血管共病患者,长期CGRP阻断的安全性担忧持续存在。
  • 双重CGRP通路阻断(单抗联合gepants)的血管风险此前未被综述,需关注。

研究设计与样本

  • 叙述性综述,聚焦CGRP靶向偏头痛治疗的心血管与脑血管安全性。
  • 比较新型CGRP靶向药物与传统偏头痛预防药物。
  • 讨论双重CGRP通路阻断在血管风险背景下的新兴话题。

主要发现

  • 临床试验与真实世界数据提示,在无主要风险因素患者中CGRP靶向治疗心血管安全性良好。
  • 在既往卒中、蛛网膜下腔出血、心肌梗死或显著心血管共病患者中数据匮乏。
  • 长期CGRP阻断在高危人群中的安全性担忧持续存在。

临床怎么用

  • 基于现有证据,为有血管风险或脑血管病患者使用CGRP靶向治疗提供结构化临床考虑。
  • 支持在常被临床试验排除但临床日益重要的人群中进行知情决策。

局限性

  • 叙述性综述,非系统评价。
  • 既往卒中、蛛网膜下腔出血、心肌梗死或显著心血管共病患者数据匮乏。
  • 双重CGRP通路阻断的血管风险证据尚未被综述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Calcitonin gene-related peptide (CGRP)-targeted therapies, including monoclonal antibodies (mAbs) and gepants, represent a major advancement in migraine prevention, offering greater efficacy and improved tolerability compared with traditional treatments. These agents selectively inhibit the CGRP pathway, a key mediator in migraine pathophysiology, and are increasingly used even as first-line options in selected patients. While clinical trials and real-world data suggest a favorable cardiovascular (CV) safety profile, particularly in patients without major risk factors, evidence remains limited for those with established vascular disease or recent vascular events. Concerns persist regarding long-term effects and the safety of CGRP blockade in high-risk populations. This narrative review focuses on the CV and cerebrovascular safety of CGRP-targeted migraine treatments-an area of growing clinical relevance. We compare these newer agents with traditional migraine preventives and highlight the paucity of data in patients with previous stroke, subarachnoid hemorrhage, myocardial infarction, or significant CV comorbidities. In addition, we discuss the emerging topic of dual CGRP pathway blockade (mAbs plus gepants), which has not previously been reviewed in the context of vascular risk. Based on currently available scientific evidence, we offer structured clinical considerations to guide the use of CGRP-targeted therapies in patients with vascular risk or cerebrovascular disease. Our aim is to support informed decision making in a population that has often been excluded from clinical trials but is becoming increasingly important in clinical practice.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Eller MT, Schwarzová K, Gufler L, et al. CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review. Neurology. 2025. PMID: 40537071. doi:10.1212/WNL.0000000000213852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。